

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Improving Miscarriage Prevention Research – a survey exploring the Expectations of Service users and Stakeholders (IMPRESS): A study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2024-085929
Article Type:	Protocol
Date Submitted by the Author:	29-Feb-2024
Complete List of Authors:	Black, Naomi; University of Warwick, Division of Biomedical Sciences, Clinical Sciences Research Laboratories; University Hospitals Coventry and Warwickshire NHS Trust Quenby, Siobhan; University of Warwick, Division of Biomedical Sciences, Clinical Sciences Research Laboratories; University Hospitals Coventry and Warwickshire NHS Trust Odendaal, Joshua; University of Warwick, Division of Biomedical Sciences, Clinical Sciences Research Laboratories; University Hospitals Coventry and Warwickshire NHS Trust,
Keywords:	Patient Participation, Research Design, Reproductive medicine < GYNAECOLOGY, Methods, GYNAECOLOGY

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12 **Improving Miscarriage Prevention Research – a survey exploring the Expectations of Service users**  
13 **and Stakeholders (IMPRESS): A study protocol**  
14

15  
16  
17 *Authors:*

18 *Naomi Black<sup>1-2</sup>, Siobhan Quenby<sup>1-2</sup>, Joshua Odendaal<sup>1-2</sup>*  
19

20  
21  
22 *Affiliations:*

23 <sup>1</sup>Division of Biomedical Sciences, Clinical Sciences Research Laboratories, Warwick Medical School,  
24 University of Warwick, Coventry CV2 2DX, United Kingdom.  
25

26 <sup>2</sup>University Hospitals Coventry & Warwickshire, Coventry CV2 2DX, United Kingdom.  
27

28  
29  
30 Corresponding Author: *Dr Naomi Black, Division of Biomedical Sciences, Warwick Medical School,*  
31 *University of Warwick, Coventry CV2 2DX, United Kingdom. Email: [naomi.black@warwick.ac.uk](mailto:naomi.black@warwick.ac.uk),*  
32

33 *ORCID ID: [0000-0002-8869-606X](https://orcid.org/0000-0002-8869-606X)*  
34

35  
36  
37 *Word count: 2026*  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Abstract:****Introduction:**

Interventional clinical trials in recurrent miscarriage use varying expected effect sizes to inform their sample size calculations. Often these are not informed by what stakeholders consider a meaningful treatment effect. Adaptive trial designs may integrate stakeholder views on trial success and futility but the criteria to inform this is lacking. This study aims to understand relevant stakeholder views of what is considered a worthwhile treatment effect for miscarriage prevention interventions and what is acceptable stopping criteria in miscarriage clinical trials.

**Methods and analysis:**

The study is designed as a cross-sectional online anonymous survey. The survey presents different scenarios to respondents relating to varying target differences and probability thresholds and explores success and futility criteria for clinical trials. The survey was developed with personal and public involvement (PPI) through focus groups and a PPI-partner. Eligible participants will be those with a personal history of miscarriage, including partners, and healthcare professionals who manage patients who experience a miscarriage. Convenience, snowball, and purposive sampling techniques will be employed to invite eligible participants to complete the survey. The survey will be accepting responses for an initial two-week pilot to check validity, prior to being open for a further 12 weeks. Descriptive analyses and linear regression analyses will synthesise the survey results.

**Ethics and dissemination:**

Ethical approval was obtained from the NHS Research Ethics Committee North West – Greater Manchester East (23/NW/0322) on 30/1/24. Informed consent will be obtained prior to survey completions. No personal identifying information will be collected. The results will be published in a relevant scientific journal and communicated through our institutional website.

**Estimated start of study:** April 2024.

**Keywords:** Abortion, Habitual; Patient Participation; Pregnancy Complications; Research Design; Sample Size

**Strengths and limitations of this study:**

- Study findings will impact future clinical trial design, ensuring representation of patient viewpoints and trials designed to identify patient and clinician meaningful treatment differences.
- This study utilises a novel survey instrument for investigating stakeholder views of miscarriage prevention treatment designed in liaison with a PPI partner and PPI input.
- A pilot phase of the survey will examine survey validity before national dissemination.
- The survey is only available in English, which may impact the diversity of viewpoints represented.
- Although some of the questions address how treatment burden may impact stakeholder's expectations of treatment difference, the range of different potential treatment burdens mean this cannot be fully explored.

## Introduction:

Miscarriage prevention is an active area of research driven by pronounced clinical need. Miscarriage, defined as the loss of a pregnancy prior to viability, poses not only physical risks but also significant psychological consequences. Regrettably, miscarriage is common, with 10% of the population experiencing at least one miscarriage and 2% experiencing recurrent miscarriage (RM), defined as two or more losses(1).

The most common cause of any early pregnancy loss is a chromosomal abnormality of the developing pregnancy(2). With higher order recurring miscarriages, the underlying causes vary and include immunological, haematological and endometrial pathologies(3). Approximately 50% of recurrent miscarriages remain unexplained and the search for causes and treatment continues(4). Due to this diversity in underlying pathologies, no single treatment to prevent miscarriage can be 100% effective. As new treatment options are developed, robust clinical trials are needed to investigate effectiveness prior to routine introduction.

Interventional clinical trials should be adequately powered to be able detect a difference between treatments if one exists. These sample size calculations combine different statistical parameters including the target difference or effect size of the treatment(5). The target difference may reflect the minimum clinically important difference or be defined by parameters set by the researchers(6). The minimum clinically important difference represents the smallest change in treatment outcomes considered clinically meaningful. The target difference is commonly informed by previous evidence, pilot studies or expert opinion and it should be considered an important difference by at least one stakeholder group(7). In practice, the target difference may be chosen for convenience with unclear supporting rationale(7).

While larger trials are required to detect smaller differences, requiring more funding and resources, it is important that the choice of target difference has a clear rationale. The target differences used in previous miscarriage prevention interventional trials vary greatly; with heterogeneity even amongst large multicentre randomised controlled trials who have aimed to detect treatment differences between 5-20%(8-12).

It is estimated that RM patients have a 50-60% chance of live birth in a future pregnancy without any intervention(9, 11, 13). This figure may increase or decrease depending on previous reproductive

1  
2  
3 history, age and other factors(14). At present, it is unknown whether stakeholders' expectations of  
4 treatment would vary at differing probabilities of live birth without intervention.  
5  
6  
7

8 Consensus on stakeholder views of a meaningful target difference is needed to inform clinical trial  
9 design and the interpretation of results. Adaptive trial designs, such as those using a Bayesian  
10 framework, may also use stakeholder views on meaningful difference to influence decisions about  
11 when to stop a trial early, if the trial meets the criteria for success or futility(15). This is important  
12 because interim analyses may find the treatment difference is very large, making it unethical to  
13 continue or that the treatment difference is not enough and that the research is futile. Currently  
14 there are no recommended criteria or relevant clinical literature to inform on the statistical  
15 thresholds for stopping or continuing recurrent miscarriage trials. Without directly involving the  
16 views of stakeholders, researchers cannot presume what should be considered a meaningful  
17 intervention.  
18  
19  
20  
21  
22  
23  
24

25  
26 This is a protocol for an online survey of stakeholders, including people who have experienced  
27 miscarriage, their partners and relevant health care professionals. The survey would aim to  
28 understand stakeholder views on a meaningful target difference and stopping criteria for  
29 miscarriage prevention trials. This research would inform future trial design, interpretation of  
30 findings and make novel contribution to adaptive trial methodology in this field.  
31  
32  
33  
34  
35  
36

### 37 **Methods:**

#### 38 *Design:*

39 An online cross-sectional survey of stakeholders will be conducted, hosted via the Qualtrics  
40 platform. The survey will be anonymous with no personally identifiable information requested.  
41  
42 This study is sponsored by the University of Warwick.  
43  
44  
45  
46  
47

#### 48 *Participants:*

49 Eligible participants include any person or their partners who have experienced miscarriage or  
50 healthcare professionals whose job role includes the care of miscarriage patients. The latter includes  
51 but is not limited to doctors working within Obstetrics & Gynaecology and nurse specialists in  
52 gynaecology, early pregnancy, and fertility. There will be no restrictions on gender, ethnicity, or  
53 social background. While the study does not aim to recruit participants under the age of 18, the  
54 survey will be available in the public domain and some respondents that fulfil the inclusion criteria  
55  
56  
57  
58  
59  
60

1  
2  
3 may be below this age. Participant information and the survey will not be available in languages  
4 other than English.  
5  
6  
7

8 *Consent:*

9  
10 All participants will be asked to confirm their consent at the start of the online survey  
11 (Supplementary material S1). The participants will only gain access to the survey questions if they  
12 indicate their consent. As the data collection process is anonymous, it will not be possible to  
13 withdraw data from the study. This will be clearly stated on the consent form.  
14  
15  
16

17  
18 *Setting:*

19  
20 The online survey will be hosted by Qualtrics, a cloud-based survey platform. Qualtrics provides a  
21 secure and user-friendly interface, allowing ease of access and survey completion by participants.  
22 Qualtrics adheres to GDPR regulations and the collection of IP addresses and physical location access  
23 will be turned off to allow complete anonymity of respondents.  
24  
25  
26

27  
28 *Recruitment:*

29  
30 Participant recruitment to the survey will be performed through four avenues.

31  
32 (1) Tommy's net (IRAS ID 213470) is a data platform that holds data from patients who have  
33 attended Tommy's national recurrent miscarriage clinics, it holds retrospective and prospective data  
34 on patient demographics and pregnancy outcomes. It facilitates research into the causes and  
35 treatment options for miscarriage patients. On recruitment to Tommy's net, patients are asked to  
36 consent to being contacted about future relevant research studies. Patients who attended the  
37 recurrent miscarriage clinic at University Hospitals Coventry and Warwickshire (UHCW), enrolled into  
38 Tommy's net and consented to be contacted about relevant future research studies will be emailed  
39 an invitation to complete this survey. The email invitation will include a link to the participant  
40 information sheet. The email will request patients share the invitation with their partners. An  
41 estimated 1800 participants are currently registered with Tommy's net via the UHCW recurrent  
42 miscarriage clinic, with most expected to be eligible for recruitment. Although this represents a  
43 single centre, referrals to the clinic are received nationally, and the cohort is diverse, as previously  
44 described(16).  
45  
46  
47  
48  
49  
50  
51  
52

53  
54  
55 (2) Recruitment posters will be displayed locally at UHCW in relevant departments, including the  
56 recurrent miscarriage clinic, the early pregnancy unit, and the fertility unit. These will be present for  
57 the duration of the study.  
58  
59  
60

1  
2  
3  
4  
5 (3) Miscarriage charities will be approached to request dissemination of the survey via their internal  
6 platforms, this may include publication on their website, inclusion in any routine newsletters and via  
7 social media channels. The Tommy's charity and The Lily Mae Foundation have already agreed to  
8 publicise the survey, with a reach of over eighty thousand social media followers.  
9

10  
11  
12  
13 (4) Healthcare professionals who work with miscarriage patients will be identified and contacted  
14 directly by email. National networks of relevant clinicians will be approached to request  
15 dissemination of the survey.  
16  
17

#### 18 19 20 *Data collection: Survey questions*

21 The survey contains 20 questions and has been developed for online completion. The questions  
22 were developed by researchers with experience in clinical trials in recurrent miscarriage and were  
23 presented to a focus group of patients, partners and clinicians held in December 2019. The survey  
24 was also reviewed by a PPI partner.  
25  
26  
27

28  
29  
30 The survey is composed of the following sections:

31 (Section 1) Respondent demographics with identification of respondents who are patients and  
32 partners and the number of previous miscarriages they have had or whether they are a healthcare  
33 professional and their clinical role.  
34

35 (Section 2) Introductory scenarios about whether they consider different treatment differences to  
36 prevent miscarriage to be worthwhile.  
37

38 (Section 3) Further scenarios examining the impact of whether additional testing prior to treatment  
39 impacts when a treatment difference is considered worthwhile.  
40

41 (Section 4) Scenarios examining respondent views on clinical trial stopping criteria at differing  
42 treatment difference thresholds.  
43

44 (Section 5) A free text answer on whether the respondent has any other thoughts on what affects  
45 whether a treatment to prevent miscarriage is worthwhile.  
46  
47

48  
49  
50  
51  
52 Visual representations of questions asking for numeric answers on treatment difference have been  
53 incorporated to improve question comprehension and survey engagement(17, 18).  
54

55  
56  
57 The survey will be piloted for two weeks to check the face validity of the questions(19). The pilot will  
58 open locally to participants recruited from UHCW. 250 participants registered with Tommy's net will  
59  
60

1  
2  
3 be emailed inviting them to complete the survey. If the response rate to this invitation is less than  
4  
5 10% or the responses indicate issues with question comprehension, the study will be stopped, and  
6  
7 the survey questions redesigned with appropriate ethical approval amendments.  
8  
9

### 10 **Management and reporting of adverse reactions:**

11 There are no risks or side effects to participants completing this survey. The survey avoids any  
12  
13 probing questions about personal miscarriage history, but it is recognised that thinking about  
14  
15 miscarriage may be distressing. Participants will be signposted to several charities that provide  
16  
17 information on miscarriage and can provide additional support in the form of a miscarriage helpline  
18  
19 and access to support groups and counselling.  
20  
21

### 22 **Patient and public involvement:**

23 There has been PPI involvement in the development of the survey questions and the patient facing  
24  
25 material. The scenarios described in the survey were presented to a focus group. The survey  
26  
27 questions and consent process were reviewed by Amy Jackson, co-founder, and operations manager  
28  
29 of the Lily-Mae Foundation. The Lily-Mae Foundation is a charity supporting those affected by  
30  
31 miscarriage, stillbirth and neonatal death.  
32  
33

### 34 **Data analysis:**

#### 35 *Sample size determination:*

36  
37 A minimum sample size of 250 respondents is proposed. This represents a modest response rate  
38  
39 from the sampling frame of Tommy's net alone and the aim is to achieve many more responses than  
40  
41 this. However, at minimum, this should provide sufficient diversity of viewpoints to guide  
42  
43 conclusions. This is a novel approach in miscarriage research, so there is no literature available to  
44  
45 guide a sample size calculation. The survey will close after being open for a two-week pilot and then  
46  
47 12-week window, regardless of number of respondents.  
48  
49

#### 50 *Data analysis plan:*

51 The survey will collect quantitative data using numeric responses or multiple-choice questions and  
52  
53 there will be one free text answer exploring any other views the respondents wish to share.  
54  
55 Quantitative analysis will be conducted using descriptive statistics to summarise the demographic  
56  
57 characteristics and survey responses. Subgroup analyses will be conducted for patients, partners and  
58  
59 healthcare professionals. Linear regression analysis is planned to assess the relationship between  
60

1  
2  
3 number of previous miscarriages and responses. Qualitative analysis of the free text question will be  
4 conducted using thematic analysis through managing software NVivo.  
5  
6  
7

### 8 **Ethical, legal and regulatory aspects:**

9

10  
11 The study will be conducted in full conformance with the principles of the Declaration of Helsinki and  
12 Good Clinical Practice (GCP) guidelines. It will comply with all applicable UK legislation and standard  
13 operating procedures from the trial sponsor. Ethical approval for this study has been granted  
14 through the NHS Research Ethics Committee (REC) North West - Greater Manchester East (REC  
15 reference: (23/NW/0322), REC approval date: 30<sup>th</sup> January 2024.  
16  
17  
18  
19

#### 20 *Data storage and patient confidentiality:*

21  
22 All study information will be held securely in accordance with the Data Protection Act 2018.  
23  
24 The data will not collect any personal identifying information. There is one free text response  
25 question, and we recognise the possibility of respondents entering identifiable information here.  
26  
27 Only the immediate study team will have access to the raw data and will ensure any potentially  
28 identifiable information included in the free text section is removed or changed. On completion of  
29 the survey, data will be extracted from the Qualtrics platform to a PGP-encrypted folder on secure  
30 institutional servers. It will be held for ten years prior to deletion. All data will be deleted  
31 permanently deleted from the Qualtrics platform.  
32  
33  
34  
35  
36  
37

### 38 **Dissemination and impact:**

39

40  
41 The findings of this research will be disseminated to academics and clinicians working within this  
42 field. The study report will be shared on our institutional website as well as by any miscarriage  
43 charities that helped disseminate the invitation to the study. The findings will be submitted for  
44 publication in a high quality, peer reviewed journal. Abstracts will be prepared for national and  
45 international conferences to further disseminate the work.  
46  
47  
48  
49

50  
51 It is hoped that the findings will inform the design and conduct of future miscarriage trials. It is  
52 anticipated that the findings will expand the knowledge base of patient and healthcare  
53 professionals' expectations of miscarriage prevention treatment.  
54  
55  
56  
57  
58  
59  
60

**Acknowledgements:** We acknowledge Dr Sophie Rees, a qualitative researcher, who was involved in the early development of this project. We also acknowledge Amy Jackson, co-founder and operations manager of The Lily-Mae Foundation, who reviewed the survey questions and consent.

**Author contributions:** JO and SQ conceived the study, it was further developed by NB. NB wrote the first draft of this publication. All authors edited, read, and approved the final version of the manuscript.

**Funding statement:** No direct funding was received for this work. NB is supported by Efficacy and Mechanism Evaluation (EME) Programme, an MRC and NIHR Partnership (Funder reference: 17/60/22). JO is an NIHR funded Academic Clinical Lecturer. The views expressed in this publication are those of the authors and do not reflect those of the MRC or NIHR.

**Competing interest statement:** The study authors have no competing interests to declare.

#### References:

1. Quenby S, Gallos ID, Dhillon-Smith RK, Podesek M, Stephenson MD, Fisher J, et al. Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss. *The Lancet*. 2021;397(10285):1658-67.
2. Melo P, Dhillon-Smith R, Islam MA, Devall A, Coomarasamy A. Genetic causes of sporadic and recurrent miscarriage. *Fertil Steril*. 2023;120(5):940-4.
3. Coomarasamy A, Dhillon-Smith RK, Papadopoulou A, Al-Memar M, Brewin J, Abrahams VM, et al. Recurrent miscarriage: evidence to accelerate action. *Lancet*. 2021;397(10285):1675-82.
4. Yu N, Kwak-Kim J, Bao S. Unexplained recurrent pregnancy loss: Novel causes and advanced treatment. *Journal of Reproductive Immunology*. 2023;155:103785.
5. Chow S-C, Shao J, Wang H, Lokhnygina Y. *Sample size calculations in clinical research*: CRC press; 2017.
6. Rothwell JC, Julious SA, Cooper CL. A study of target effect sizes in randomised controlled trials published in the Health Technology Assessment journal. *Trials*. 2018;19(1):544.
7. Cook JA, Julious SA, Sones W, Hampson LV, Hewitt C, Berlin JA, et al. DELTA2 guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial. *Trials*. 2018;19(1):606.

- 1  
2  
3 8. de Jong PGQ, Siobhan; Bloemenkamp, Kitty W M; Braams-Lisman, Babette A M; de Bruin,  
4 Jan Peter; Coomarasamy, Arri; David, Michele; DeSancho, Maria T; van der Heijden, Olivier W H;  
5 Hoek, Annemieke; Hutten, Barbara A; Jochmans, Kristin; Koks, Carolien A M; Kuchenbecker, Walter K  
6 M; Mol, Ben Willem J; Torrance, Helen L; Scheepers, Hubertina C J; Stephenson, Mary D; Verhoeve,  
7 Harold R; Visser, Jantien; de Vries, Johanna I P; Goddijn, Mariette; Middeldorp, Saskia. ALIFE2 study:  
8 low-molecular-weight heparin for women with recurrent miscarriage and inherited thrombophilia--  
9 study protocol for a randomized controlled trial. *Trials*. 2015;16(101263253):208.
- 10  
11 9. Coomarasamy AW, Helen; Truchanowicz, Ewa; Seed, Paul T; Small, Rachel; Quenby, Siobhan;  
12 Gupta, Pratima; Dawood, Feroza; Koot, Yvonne E; Atik, Ruth Bender; Bloemenkamp, Kitty Wm;  
13 Brady, Rebecca; Briley, Annette; Cavallaro, Rebecca; Cheong, Ying C; Chu, Justin; Eapen, Abey; Essex,  
14 Holly; Ewies, Ayman; Hoek, Annemieke; Kaaijk, Eugenie M; Koks, Carolien A; Li, Tin-Chiu; MacLean,  
15 Marjory; Mol, Ben W; Moore, Judith; Parrott, Steve; Ross, Jackie A; Sharpe, Lisa; Stewart, Jane;  
16 Trepel, Dominic; Vaithilingam, Nirmla; Farquharson, Roy G; Kilby, Mark David; Khalaf, Yacoub;  
17 Goddijn, Mariette; Regan, Lesley; Rai, Rajendra. PROMISE: first-trimester progesterone therapy in  
18 women with a history of unexplained recurrent miscarriages - a randomised, double-blind, placebo-  
19 controlled, international multicentre trial and economic evaluation. *Health technology assessment*  
20 (Winchester, England). 2016;20(41):1-92.
- 21  
22 10. Coomarasamy A, Devall AJ, Cheed V, Harb H, Middleton LJ, Gallos ID, et al. A Randomized  
23 Trial of Progesterone in Women with Bleeding in Early Pregnancy. *New England Journal of Medicine*.  
24 2019;380(19):1815-24.
- 25  
26 11. Dhillon-Smith RK, Middleton LJ, Sunner KK, Cheed V, Baker K, Farrell-Carver S, et al.  
27 Levothyroxine in Women with Thyroid Peroxidase Antibodies before Conception. *New England*  
28 *Journal of Medicine*. 2019;380(14):1316-25.
- 29  
30 12. Vissenberg R, van Dijk MM, Fliers E, van der Post JAM, van Wely M, Bloemenkamp KWM, et  
31 al. Effect of levothyroxine on live birth rate in euthyroid women with recurrent miscarriage and TPO  
32 antibodies (T4-LIFE study). *Contemp Clin Trials*. 2015;44:134-8.
- 33  
34 13. Quenby SB, K; Hiller, L; Coomarasamy, A; de Jong, PG; Hamulyák, EN; Scheres, LJ; van Haaps,  
35 TF; Ewington, L; Tewary, S; et al.,. Heparin for women with recurrent miscarriage and inherited  
36 thrombophilia (ALIFE2): an international open-label, randomised controlled trial.  
37 2023;402(10395):54-61.
- 38  
39 14. Kolte AM, Westergaard D, Lidegaard Ø, Brunak S, Nielsen HS. Chance of live birth: a  
40 nationwide, registry-based cohort study. *Human Reproduction*. 2021;36(4):1065-73.
- 41  
42 15. Giovagnoli A. The Bayesian Design of Adaptive Clinical Trials. *Int J Environ Res Public Health*.  
43 2021;18(2).

- 1  
2  
3 16. Shields R, Khan O, Keung SLC, Hawkes AJ, Barry A, Devall AJ, et al. Quantitative assessment  
4 of pregnancy outcome following recurrent miscarriage clinic care: a prospective cohort study. *BMJ*  
5 *Open*. 2022;12(2):e052661.  
6  
7  
8 17. Edwards P. Questionnaires in clinical trials: guidelines for optimal design and administration.  
9 *Trials*. 2010;11(1):2.  
10  
11 18. Shr Y-H, Ready R, Orland B, Echols S. How Do Visual Representations Influence Survey  
12 Responses? Evidence from a Choice Experiment on Landscape Attributes of Green Infrastructure.  
13 *Ecological Economics*. 2019;156:375-86.  
14  
15 19. Taherdoost H. Validity and reliability of the research instrument; how to test the validation  
16 of a questionnaire/survey in a research. How to test the validation of a questionnaire/survey in a  
17 research (August 10, 2016). 2016.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Supplementary material: S1 – Consent for IMPRESS Survey

**Study Title:** Improving Miscarriage Prevention Research – a survey exploring the Expectations of Service users and Stakeholders (IMPRESS)

**Study investigators:** Dr Joshua Odendaal, Dr Naomi Black and colleagues at the University of Warwick

Thank you for your interest in completing this short survey. This survey contains 20 questions and will take 15 minutes to complete.

This survey aims to find out what people think about the potential effectiveness of treatments for miscarriage prevention. This survey is intended for women with a history of miscarriage, their partners and healthcare professionals that are involved in treating miscarriage.

Your participation is voluntary. You can withdraw at any time whilst completing the questionnaire, and for any reason, simply by closing your browser. All responses will be anonymous, and we do not ask for any personal identifiable information. This means that once your responses have been submitted it will not be possible to withdraw your data as your individual responses cannot be identified.

This survey does not ask probing questions about previous miscarriage experiences; however, we recognise that reflecting on the subject of miscarriage may cause some participants to feel upset. Please remember that you are free to withdraw during completion of the survey. You may find it useful to find out more information about miscarriage and the support available for you at this time. Useful information sources include Tommy's, The Miscarriage Association and The Lily Mae foundation. You can find out more by clicking on the icons below.



Throughout the survey, we use the word 'woman' for ease of reading, but we recognise that it is possible for someone who does not identify as a woman to experience miscarriage.

This study has been granted ethical approval by NHS Health Research Authority (HRA), IRAS reference: 314809

No funding was received for completion of this project. This work will contribute to a doctoral thesis.

1  
2  
3  
4  
5 Data will be securely stored on the University of Warwick servers in password protected files. Access to the data  
6 will be restricted to the study investigators alone. Summaries may be presented at conferences and included in  
7 scientific publications. Data will be reviewed on completion of the research, in line with the University of Warwick  
8 data retention policy. More information about the University of Warwick Research data and privacy notice are  
9 available here: <https://warwick.ac.uk/services/idc/dataprotection/privacynotes/researchprivacynote>.

10  
11  
12  
13  
14  
15 If you require any further information, please contact the study team: [impress@warwick.ac.uk](mailto:impress@warwick.ac.uk)

16  
17  
18 If you wish to make a complaint about this study, please address your complaint the Research & Impact Services  
19 at [researchgovernance@warwick.ac.uk](mailto:researchgovernance@warwick.ac.uk), if the complaint related to how we have handled your personal data  
20 please address your complaint to the Data Protection Officer at [DPO@warwick.ac.uk](mailto:DPO@warwick.ac.uk).

21  
22  
23  
24  
25 Further details about the study and the complaint process can be accessed here: (Link to full PIS)

## 26 27 28 **Consent**

- 29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49
1. I confirm that I have read and understand the information for the above study. I have had the opportunity to consider the information, ask questions and have had these answered satisfactorily.
  2. I understand that my participation is voluntary and that I am free to withdraw at any time whilst completing the questionnaire without giving any reason.
  3. I understand that any data I enter cannot be removed from the study once submitted.
  4. I understand that data collected during the study, may be looked at by individuals from the University of Warwick where it is relevant to my taking part in this study. I give permission for these individuals to have access to my data.
  5. I consent for this data to be used for research purposes to investigate views on the effectiveness of miscarriage treatment in clinical research trials.
  6. I confirm that it is my first time completing the survey.

50  
51  
52 I have read the above and:

53  
54  
55 I consent to take part in this study

56  
57  
58 I do not wish to participate

# BMJ Open

## Improving Miscarriage Prevention Research – a survey exploring the Expectations of Service users and Stakeholders (IMPRESS): A study protocol for a UK based survey

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2024-085929.R1
Article Type:	Protocol
Date Submitted by the Author:	02-May-2024
Complete List of Authors:	Black, Naomi; University of Warwick, Division of Biomedical Sciences, Clinical Sciences Research Laboratories; University Hospitals Coventry and Warwickshire NHS Trust Quenby, Siobhan; University of Warwick, Division of Biomedical Sciences, Clinical Sciences Research Laboratories; University Hospitals Coventry and Warwickshire NHS Trust Odendaal, Joshua; University of Warwick, Division of Biomedical Sciences, Clinical Sciences Research Laboratories; University Hospitals Coventry and Warwickshire NHS Trust,
<b>Primary Subject Heading</b>:	Obstetrics and gynaecology
Secondary Subject Heading:	Obstetrics and gynaecology
Keywords:	Patient Participation, Research Design, Reproductive medicine < GYNAECOLOGY, Methods, GYNAECOLOGY

SCHOLARONE™  
Manuscripts

1  
2  
3 1  
4  
5 2  
6  
7 3  
8  
9 4  
10  
11 5  
12 6 **Improving Miscarriage Prevention Research – a survey exploring the Expectations of Service users**  
13 7 **and Stakeholders (IMPRESS): A study protocol for a UK based survey**  
14  
15 8

16  
17 9 *Authors:*

18 10 *Naomi Black<sup>1-2</sup>, Siobhan Quenby<sup>1-2</sup>, Joshua Odendaal<sup>1-2</sup>*

21  
22 12 *Affiliations:*

23 13 <sup>1</sup>Division of Biomedical Sciences, Clinical Sciences Research Laboratories, Warwick Medical School,  
24 14 University of Warwick, Coventry CV2 2DX, United Kingdom.

25 15 <sup>2</sup>University Hospitals Coventry & Warwickshire, Coventry CV2 2DX, United Kingdom.

26  
27 16  
28  
29  
30 17 Corresponding Author: *Dr Naomi Black, Division of Biomedical Sciences, Warwick Medical School,*  
31  
32 18 *University of Warwick, Coventry CV2 2DX, United Kingdom. Email: [naomi.black@warwick.ac.uk](mailto:naomi.black@warwick.ac.uk),*

33 19 *ORCID ID: [0000-0002-8869-606X](https://orcid.org/0000-0002-8869-606X)*

34 20  
35 21  
36 22  
37 23  
38 24  
39 25  
40 26  
41 27  
42 28  
43 29  
44 30  
45 31  
46 32  
47 33  
48 34  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Word count: 2296

1  
2  
3 **35 Abstract:**  
4

5 **36**  
6 **37 Introduction:**  
7  
8 **38**

9  
10 **39** Interventional clinical trials in recurrent miscarriage use varying expected effect sizes to inform their  
11 **40** sample size calculations. Often these are not informed by what stakeholders consider a meaningful  
12 **41** treatment effect. Adaptive trial designs may integrate stakeholder views on trial success and futility  
13 **42** but the criteria to inform this is lacking. This study aims to understand relevant stakeholder views of  
14 **43** what is considered a worthwhile treatment effect for miscarriage prevention interventions and what  
15 **44** is acceptable stopping criteria in miscarriage clinical trials.  
16  
17  
18  
19

20 **45**  
21 **46 Methods and analysis:**  
22  
23 **47**

24  
25 **48** The study is designed as a cross-sectional online anonymous survey. The survey presents different  
26 **49** scenarios to respondents relating to varying target differences and probability thresholds and  
27 **50** explores success and futility criteria for clinical trials. The survey was developed with personal and  
28 **51** public involvement (PPI) through focus groups and a PPI-partner. Eligible participants will be those  
29 **52** with a personal history of miscarriage, including partners, and healthcare professionals who manage  
30 **53** patients who experience a miscarriage. Convenience, snowball, and purposive sampling techniques  
31 **54** will be employed to invite eligible participants to complete the survey. The survey will be accepting  
32 **55** responses for an initial two-week pilot to check validity, prior to being open for a further 12 weeks.  
33 **56** Descriptive analyses and linear regression analyses will synthesise the survey results.  
34  
35  
36  
37  
38  
39  
40  
41

42 **58 Ethics and dissemination:**  
43  
44 **59**

45 **60** Ethical approval was obtained from the NHS Research Ethics Committee North West – Greater  
46 **61** Manchester East (23/NW/0322) on 30/1/24. Informed consent will be obtained prior to survey  
47 **62** completions. No personal identifying information will be collected. The results will be published in a  
48 **63** relevant scientific journal and communicated through our institutional website.  
49  
50  
51  
52

53 **65 Estimated start of study:** April 2024.  
54  
55  
56

57 **67 Keywords:** Abortion, Habitual; Patient Participation; Pregnancy Complications; Research Design;  
58 **68** Sample Size  
59  
60

1  
2  
3 69 **Strengths and limitations of this study:**  
4  
5 70

- 6 71 • Study findings will impact future clinical trial design, ensuring representation of patient  
7 viewpoints and trials designed to identify patient and clinician meaningful treatment  
8 72 differences.  
9  
10 73  
11 74 • This study utilises a novel survey instrument for investigating stakeholder views of  
12 miscarriage prevention treatment designed in liaison with a PPI partner and PPI input.  
13 75  
14 76 • A pilot phase of the survey will examine survey validity before national dissemination.  
15 77  
16 77 • The survey is only available in English, which may impact the diversity of viewpoints  
17 represented.  
18 78  
19  
20 79 • Although some of the questions address how treatment burden may impact stakeholder's  
21 expectations of treatment difference, the range of different potential treatment burdens  
22 80 mean this cannot be fully explored.  
23 81  
24  
25 82  
26  
27 83  
28  
29 84  
30 85  
31  
32 86  
33  
34 87  
35 88  
36  
37 89  
38  
39 90  
40 91  
41  
42 92  
43  
44 93  
45 94  
46  
47 95  
48  
49 96  
50 97  
51  
52 98  
53  
54 99  
55 100  
56  
57 101  
58  
59 102  
60

1  
2  
3 **103 Introduction:**  
4

5 104

6 105 Miscarriage prevention is an active area of research driven by pronounced clinical need. Miscarriage,  
7  
8 106 defined as the loss of a pregnancy prior to viability, poses not only physical risks but also significant  
9  
10 107 psychological consequences. Regrettably, miscarriage is common, with 10% of the population  
11  
12 108 experiencing at least one miscarriage and 2% experiencing recurrent miscarriage (RM), defined as  
13  
14 109 two or more losses(1).  
15

16 110

17 111 The most common cause of any early pregnancy loss is a chromosomal abnormality of the  
18  
19 112 developing pregnancy(2). With higher order recurring miscarriages, the underlying causes vary and  
20  
21 113 include immunological, haematological and endometrial pathologies(3). Approximately 50% of  
22  
23 114 recurrent miscarriages remain unexplained and the search for causes and treatment continues(4).  
24  
25 115 Due to this diversity in underlying pathologies, no single treatment to prevent miscarriage can be  
26  
27 116 100% effective. As new treatment options are developed, robust clinical trials are needed to  
28  
29 117 investigate effectiveness prior to routine introduction.  
30

31 118

32 119 Interventional clinical trials should be adequately powered to be able detect a difference between  
33  
34 120 treatments if one exists. These sample size calculations combine different statistical parameters  
35  
36 121 including the target difference or effect size of the treatment(5). The target difference may reflect  
37  
38 122 the minimum clinically important difference or be defined by parameters set by the researchers(6).  
39  
40 123 The minimum clinically important difference represents the smallest change in treatment outcomes  
41  
42 124 considered clinically meaningful. The target difference is commonly informed by previous evidence,  
43  
44 125 pilot studies or expert opinion and it should be considered an important difference by at least one  
45  
46 126 stakeholder group(7). In practice, the target difference may be chosen for convenience with unclear  
47  
48 127 supporting rationale(7).  
49

50 128

51 129 While larger trials are required to detect smaller differences, requiring more funding and resources,  
52  
53 130 it is important that the choice of target difference has a clear rationale. The target differences used  
54  
55 131 in previous miscarriage prevention interventional trials vary greatly; with heterogeneity even  
56  
57 132 amongst large multicentre randomised controlled trials who have aimed to detect treatment  
58  
59 133 differences between 5-20%(8-12).  
60

60 134

61 135 It is estimated that RM patients have a 50-60% chance of live birth in a future pregnancy without any  
62  
63 136 intervention(9, 11, 13). This figure may increase or decrease depending on previous reproductive

1  
2  
3 137 history, age and other factors(14). At present, it is unknown whether stakeholders' expectations of  
4  
5 138 treatment would vary at differing probabilities of live birth without intervention.

6 139  
7  
8 140 Consensus on stakeholder views of a meaningful target difference is needed to inform clinical trial  
9  
10 141 design and the interpretation of results. Adaptive trial designs, such as those using a Bayesian  
11  
12 142 framework, may also use stakeholder views on meaningful difference to influence decisions about  
13  
14 143 when to stop a trial early, if the trial meets the criteria for success or futility(15). This is important  
15  
16 144 because interim analyses may find the treatment difference is very large, making it unethical to  
17  
18 145 continue or that the treatment difference is not enough and that the research is futile. Currently  
19  
20 146 there are no recommended criteria or relevant clinical literature to inform on the statistical  
21  
22 147 thresholds for stopping or continuing recurrent miscarriage trials. Without directly involving the  
23  
24 148 views of stakeholders, researchers cannot presume what should be considered a meaningful  
25  
26 149 intervention.

27 150  
28 151 This is a protocol for an online survey of stakeholders, including people who have experienced  
29  
30 152 miscarriage, their partners and relevant health care professionals. The survey would aim to  
31  
32 153 understand stakeholder views on a meaningful target difference and stopping criteria for  
33  
34 154 miscarriage prevention trials. This research would inform future trial design, interpretation of  
35  
36 155 findings and make novel contribution to adaptive trial methodology in this field.

37 156

#### 37 157 **Methods:**

38 158

##### 39 159 *Design:*

40 160 An online cross-sectional survey of stakeholders will be conducted, hosted via the Qualtrics  
41  
42 161 platform. The survey will be anonymous with no personally identifiable information requested.  
43  
44 162 This study is sponsored by the University of Warwick.

##### 45 163 *Participants:*

46  
47 164 Eligible participants include any person or their partners who have experienced miscarriage or  
48  
49 165 healthcare professionals whose job role includes the care of miscarriage patients. The latter includes  
50  
51 166 but is not limited to doctors working within Obstetrics & Gynaecology and nurse specialists in  
52  
53 167 gynaecology, early pregnancy, and fertility. There will be no restrictions on gender, ethnicity, or  
54  
55 168 social background. While the study does not aim to recruit participants under the age of 18, the  
56  
57 169 survey will be available in the public domain and some respondents that fulfil the inclusion criteria

170 may be below this age. Participant information and the survey will not be available in languages  
171 other than English.

172

173 *Consent:*

174 All participants will be asked to confirm their consent at the start of the online survey  
175 (Supplementary material S1). The participants will only gain access to the survey questions if they  
176 indicate their consent. As the data collection process is anonymous, it will not be possible to  
177 withdraw data from the study. This will be clearly stated on the consent form.

178

179 *Setting:*

180 The online survey will be hosted by Qualtrics, a cloud-based survey platform. Qualtrics provides a  
181 secure and user-friendly interface, allowing ease of access and survey completion by participants.  
182 Qualtrics adheres to GDPR regulations and the collection of IP addresses and physical location access  
183 will be turned off to allow complete anonymity of respondents.

184

185 *Recruitment:*

186 Participant recruitment to the survey will be performed through four avenues.

187 (1) Tommy's net (IRAS ID 213470) is a data platform that holds data from patients who have  
188 attended Tommy's national recurrent miscarriage clinics, it holds retrospective and prospective data  
189 on patient demographics and pregnancy outcomes. It facilitates research into the causes and  
190 treatment options for miscarriage patients. On recruitment to Tommy's net, patients are asked to  
191 consent to being contacted about future relevant research studies. Patients who attended the  
192 recurrent miscarriage clinic at University Hospitals Coventry and Warwickshire (UHCW), enrolled into  
193 Tommy's net and consented to be contacted about relevant future research studies will be emailed  
194 an invitation to complete this survey. The email invitation will include a link to the participant  
195 information sheet. The email will request patients share the invitation with their partners. An  
196 estimated 1800 participants are currently registered with Tommy's net via the UHCW recurrent  
197 miscarriage clinic, with most expected to be eligible for recruitment. Although this represents a  
198 single centre, referrals to the clinic are received nationally, and the cohort is diverse, as previously  
199 described(16).

200

201 (2) Recruitment posters will be displayed locally at UHCW in relevant departments, including the  
202 recurrent miscarriage clinic, the early pregnancy unit, and the fertility unit. These will be present for  
203 the duration of the study.

204

(3) Miscarriage charities will be approached to request dissemination of the survey via their internal platforms, this may include publication on their website, inclusion in any routine newsletters and via social media channels. The Tommy's charity and The Lily Mae Foundation have already agreed to publicise the survey, with a reach of over eighty thousand social media followers.

209

(4) Healthcare professionals who work with miscarriage patients will be identified and contacted directly by email. National networks of relevant clinicians will be approached to request dissemination of the survey.

213

#### *Data collection: Survey questions*

The survey contains 20 questions and has been developed for online completion. The questions were developed by researchers with experience in clinical trials in recurrent miscarriage and were presented to a focus group of patients, partners and clinicians held in December 2019. The survey was also reviewed by a PPI partner, Amy Jackson from The Lily Mae Foundation. The full survey is available is provided in the Supplementary material (S1).

220

The survey is composed of the following sections:

(Section 1) Respondent demographics with identification of respondents who are patients and partners and the number of previous miscarriages they have had or whether they are a healthcare professional and their clinical role.

(Section 2) Introductory scenarios about whether they consider different treatment differences to prevent miscarriage to be worthwhile.

(Section 3) Further scenarios examining the impact of whether additional testing prior to treatment impacts when a treatment difference is considered worthwhile.

(Section 4) Scenarios examining respondent views on clinical trial stopping criteria at differing treatment difference thresholds.

(Section 5) A free text answer on whether the respondent has any other thoughts on what affects whether a treatment to prevent miscarriage is worthwhile.

233

Visual representations of questions asking for numeric answers on treatment difference have been incorporated to improve question comprehension and survey engagement(17, 18).

236

237 The survey will be piloted for two weeks to check the face validity of the questions(19). The pilot will  
238 open locally to participants recruited from UHCW. 250 participants registered with Tommy's net will  
239 be emailed inviting them to complete the survey. If the response rate to this invitation is less than  
240 10% or the responses indicate issues with question comprehension, the study will be stopped, and  
241 the survey questions redesigned with appropriate ethical approval amendments.

242

#### 243 *Outcomes:*

244 This study aims to understand stakeholder views on a meaningful target difference and stopping  
245 criteria for miscarriage prevention trials. The primary outcome will be meaningful target difference if  
246 there is a 50% chance of having a successful pregnancy without the new treatment. Secondary  
247 outcomes will look at whether varying the likelihood of successful pregnancy without treatment  
248 affects what the respondent considers a meaningful target difference, the effect of investigation  
249 invasiveness on consideration of meaningful target difference and thresholds for stopping criteria in  
250 clinical trials.

251

#### 252 *Study timelines:*

253 The survey is planned to commence on 29<sup>nd</sup> April 2024. It will be open for a two-week local pilot,  
254 followed by national dissemination for 12 weeks. The anticipated close date of the survey is 5<sup>th</sup>  
255 August 2024. It is expected that data analysis and the manuscript will be complete by 1<sup>st</sup> December  
256 2024.

257

#### 258 **Management and reporting of adverse reactions:**

259 There are no risks or side effects to participants completing this survey. The survey avoids any  
260 probing questions about personal miscarriage history, but it is recognised that thinking about  
261 miscarriage may be distressing. Participants will be signposted to several charities that provide  
262 information on miscarriage and can provide additional support in the form of a miscarriage helpline  
263 and access to support groups and counselling.

264

#### 265 **Patient and public involvement:**

266 There has been PPI involvement in the development of the survey questions and the patient facing  
267 material. The scenarios described in the survey were presented to an established focus group within  
268 our miscarriage research unit called 'Public Involvement in Pregnancy Research (PIPR). The focus  
269 group had fourteen participants: eight patients, one partner, three midwives and two doctors. The  
270 survey questions and consent process were reviewed by Amy Jackson, our PPI partner. Amy Jackson

1  
2  
3 271 is the co-founder, and operations manager of the Lily-Mae Foundation. The Lily-Mae Foundation is a  
4  
5 272 charity supporting those affected by miscarriage, stillbirth and neonatal death.  
6  
7 273

8 274 **Data analysis:**  
9

10 275

11 276 *Sample size determination:*

12  
13 277 A minimum sample size of 250 respondents is proposed. This represents a modest response rate  
14  
15 278 from the sampling frame of Tommy's net alone and the aim is to achieve many more responses than  
16  
17 279 this. However, at minimum, this should provide sufficient diversity of viewpoints to guide  
18  
19 280 conclusions. This is a novel approach in miscarriage research, so there is no literature available to  
20  
21 281 guide a sample size calculation. The survey will close after being open for a two-week pilot and then  
22  
23 282 12-week window, regardless of number of respondents.  
24

25 283

26 284 *Data analysis plan:*

27 285 The survey will collect quantitative data using numeric responses or multiple-choice questions and  
28  
29 286 there will be one free text answer exploring any other views the respondents wish to share.

30 287 Quantitative analysis will be conducted using descriptive statistics to summarise the demographic  
31  
32 288 characteristics and survey responses. Means and standard deviations will be calculated for  
33  
34 289 continuous variables, while frequencies and percentages will be produced for categorical variables.  
35  
36 290 Subgroup analyses will be conducted for patients, partners and healthcare professionals using the  
37  
38 291 Kruskal-Wallis statistic to investigate for significant differences in the primary and secondary  
39  
40 292 outcomes results between groups. Linear regression analysis is planned to assess the relationship  
41  
42 293 between demographics including whether a patient, partner or HCP, number of previous  
43  
44 294 miscarriages, HCP role and the primary and secondary outcomes. Where there is greater than 10%  
45  
46 295 missing data for a question, we will perform multiple imputation using the fully conditional  
47  
48 296 specification approach. Qualitative analysis of the free text question will be conducted using  
49  
50 297 thematic analysis through managing software NVivo.  
51

52 298

53 299 **Data storage and patient confidentiality:**

54 300 All study information will be held securely in accordance with the Data Protection Act 2018.  
55  
56 301 The data will not collect any personal identifying information. There is one free text response  
57  
58 302 question, and we recognise the possibility of respondents entering identifiable information here.  
59  
60 303 Only the immediate study team will have access to the raw data and will ensure any potentially  
60 304 identifiable information included in the free text section is removed or changed. On completion of

1  
2  
3 305 the survey, data will be extracted from the Qualtrics platform to a PGP-encrypted folder on secure  
4  
5 306 institutional servers. It will be held for ten years prior to deletion. All data will be deleted  
6  
7 307 permanently deleted from the Qualtrics platform.  
8  
9 308

10 309 **Ethics and dissemination:**  
11  
12 310

13 311 The study will be conducted in full conformance with the principles of the Declaration of Helsinki and  
14  
15 312 Good Clinical Practice (GCP) guidelines. It will comply with all applicable UK legislation and standard  
16  
17 313 operating procedures from the trial sponsor. Ethical approval for this study has been granted  
18  
19 314 through the NHS Research Ethics Committee (REC) North West - Greater Manchester East (REC  
20  
21 315 reference: (23/NW/0322), REC approval date: 30<sup>th</sup> January 2024 and HRA approval date: 5<sup>th</sup> March  
22  
23 316 2024.  
24  
25 317  
26  
27 318  
28  
29 319

30 320 The findings of this research will be disseminated to academics and clinicians working within this  
31  
32 321 field. The study report will be shared on our institutional website as well as by any miscarriage  
33  
34 322 charities that helped disseminate the invitation to the study. The findings will be submitted for  
35  
36 323 publication in a high quality, peer reviewed journal. Abstracts will be prepared for national and  
37  
38 324 international conferences to further disseminate the work.  
39  
40 325

41 326 It is hoped that the findings will inform the design and conduct of future miscarriage trials. It is  
42  
43 327 anticipated that the findings will expand the knowledge base of patient and healthcare  
44  
45 328 professionals' expectations of miscarriage prevention treatment.  
46  
47 329  
48  
49 330

50 331 **Acknowledgements:** *We acknowledge Dr Sophie Rees, a qualitative researcher, who was involved in*  
51  
52 332 *the early development of this project. We also acknowledge Amy Jackson, co-founder and operations*  
53  
54 333 *manager of The Lily-Mae Foundation, who reviewed the survey questions and consent.*  
55  
56 334

57 335 **Author contributions:** *JO and SQ conceived the study, it was further developed by NB. NB wrote the*  
58  
59 336 *first draft of this publication. All authors edited, read, and approved the final version of the*  
60  
337 *manuscript. Joshua Odendaal is the guarantor for this work.*

1  
2  
3 338 **Funding statement:** No direct funding was received for this work. NB is supported by Efficacy and  
4  
5 339 Mechanism Evaluation (EME) Programme, an MRC and NIHR Partnership (Funder reference:  
6  
7 340 17/60/22). JO is an NIHR funded Academic Clinical Lecturer. The views expressed in this publication  
8  
9 341 are those of the authors and do not reflect those of the MRC or NIHR.

10 342

11 343 **Competing interest statement:** The study authors have no competing interests to declare.

12 344

13 345 **References:**

14 346

- 15 347 1. Quenby S, Gallos ID, Dhillon-Smith RK, Podsek M, Stephenson MD, Fisher J, et al.  
16 348 Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early  
17 349 pregnancy loss. *The Lancet*. 2021;397(10285):1658-67.
- 18 350 2. Melo P, Dhillon-Smith R, Islam MA, Devall A, Coomarasamy A. Genetic causes of sporadic  
19 351 and recurrent miscarriage. *Fertil Steril*. 2023;120(5):940-4.
- 20 352 3. Coomarasamy A, Dhillon-Smith RK, Papadopoulou A, Al-Memar M, Brewin J, Abrahams VM,  
21 353 et al. Recurrent miscarriage: evidence to accelerate action. *Lancet*. 2021;397(10285):1675-82.
- 22 354 4. Yu N, Kwak-Kim J, Bao S. Unexplained recurrent pregnancy loss: Novel causes and advanced  
23 355 treatment. *Journal of Reproductive Immunology*. 2023;155:103785.
- 24 356 5. Chow S-C, Shao J, Wang H, Lokhnygina Y. *Sample size calculations in clinical research*: CRC  
25 357 press; 2017.
- 26 358 6. Rothwell JC, Julious SA, Cooper CL. A study of target effect sizes in randomised controlled  
27 359 trials published in the Health Technology Assessment journal. *Trials*. 2018;19(1):544.
- 28 360 7. Cook JA, Julious SA, Sones W, Hampson LV, Hewitt C, Berlin JA, et al. DELTA2 guidance on  
29 361 choosing the target difference and undertaking and reporting the sample size calculation for a  
30 362 randomised controlled trial. *Trials*. 2018;19(1):606.
- 31 363 8. de Jong PGQ, Siobhan; Bloemenkamp, Kitty W M; Braams-Lisman, Babette A M; de Bruin,  
32 364 Jan Peter; Coomarasamy, Arri; David, Michele; DeSancho, Maria T; van der Heijden, Olivier W H;  
33 365 Hoek, Annemieke; Hutten, Barbara A; Jochmans, Kristin; Koks, Carolien A M; Kuchenbecker, Walter K  
34 366 M; Mol, Ben Willem J; Torrance, Helen L; Scheepers, Hubertina C J; Stephenson, Mary D; Verhoeve,  
35 367 Harold R; Visser, Jantien; de Vries, Johanna I P; Goddijn, Mariette; Middeldorp, Saskia. ALIFE2 study:  
36 368 low-molecular-weight heparin for women with recurrent miscarriage and inherited thrombophilia--  
37 369 study protocol for a randomized controlled trial. *Trials*. 2015;16(101263253):208.
- 38 370 9. Coomarasamy AW, Helen; Truchanowicz, Ewa; Seed, Paul T; Small, Rachel; Quenby, Siobhan;  
39 371 Gupta, Pratima; Dawood, Feroza; Koot, Yvonne E; Atik, Ruth Bender; Bloemenkamp, Kitty Wm;

- 1  
2  
3 372 Brady, Rebecca; Briley, Annette; Cavallaro, Rebecca; Cheong, Ying C; Chu, Justin; Eapen, Abey; Essex,  
4 373 Holly; Ewies, Ayman; Hoek, Annemieke; Kaaijk, Eugenie M; Koks, Carolien A; Li, Tin-Chiu; MacLean,  
5 374 Marjory; Mol, Ben W; Moore, Judith; Parrott, Steve; Ross, Jackie A; Sharpe, Lisa; Stewart, Jane;  
6 375 Trepel, Dominic; Vaithilingam, Nirmala; Farquharson, Roy G; Kilby, Mark David; Khalaf, Yacoub;  
7  
8 376 Goddijn, Mariette; Regan, Lesley; Rai, Rajendra. PROMISE: first-trimester progesterone therapy in  
9 377 women with a history of unexplained recurrent miscarriages - a randomised, double-blind, placebo-  
10 378 controlled, international multicentre trial and economic evaluation. Health technology assessment  
11 379 (Winchester, England). 2016;20(41):1-92.
- 12  
13  
14  
15  
16 380 10. Coomarasamy A, Devall AJ, Cheed V, Harb H, Middleton LJ, Gallos ID, et al. A Randomized  
17 381 Trial of Progesterone in Women with Bleeding in Early Pregnancy. New England Journal of Medicine.  
18 382 2019;380(19):1815-24.
- 19  
20 383 11. Dhillon-Smith RK, Middleton LJ, Sunner KK, Cheed V, Baker K, Farrell-Carver S, et al.  
21 384 Levothyroxine in Women with Thyroid Peroxidase Antibodies before Conception. New England  
22 385 Journal of Medicine. 2019;380(14):1316-25.
- 23  
24 386 12. Vissenberg R, van Dijk MM, Fliers E, van der Post JAM, van Wely M, Bloemenkamp KWM, et  
25 387 al. Effect of levothyroxine on live birth rate in euthyroid women with recurrent miscarriage and TPO  
26 388 antibodies (T4-LIFE study). Contemp Clin Trials. 2015;44:134-8.
- 27  
28 389 13. Quenby SB, K; Hiller, L; Coomarasamy, A; de Jong, PG; Hamulyák, EN; Scheres, LJ; van Haaps,  
29 390 TF; Ewington, L; Tewary, S; et al.,. Heparin for women with recurrent miscarriage and inherited  
30 391 thrombophilia (ALIFE2): an international open-label, randomised controlled trial.  
31 392 2023;402(10395):54-61.
- 32  
33 393 14. Kolte AM, Westergaard D, Lidegaard Ø, Brunak S, Nielsen HS. Chance of live birth: a  
34 394 nationwide, registry-based cohort study. Human Reproduction. 2021;36(4):1065-73.
- 35  
36 395 15. Giovagnoli A. The Bayesian Design of Adaptive Clinical Trials. Int J Environ Res Public Health.  
37 396 2021;18(2).
- 38  
39 397 16. Shields R, Khan O, Keung SLC, Hawkes AJ, Barry A, Devall AJ, et al. Quantitative assessment  
40 398 of pregnancy outcome following recurrent miscarriage clinic care: a prospective cohort study. BMJ  
41 399 Open. 2022;12(2):e052661.
- 42  
43 400 17. Edwards P. Questionnaires in clinical trials: guidelines for optimal design and administration.  
44 401 Trials. 2010;11(1):2.
- 45  
46 402 18. Shr Y-H, Ready R, Orland B, Echols S. How Do Visual Representations Influence Survey  
47 403 Responses? Evidence from a Choice Experiment on Landscape Attributes of Green Infrastructure.  
48 404 Ecological Economics. 2019;156:375-86.
- 49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 405 19. Taherdoost H. Validity and reliability of the research instrument; how to test the validation  
4 of a questionnaire/survey in a research. How to test the validation of a questionnaire/survey in a  
5 406  
6 407 research (August 10, 2016). 2016.  
7  
8 408  
9

For peer review only

Enseignement Supérieur (ABES) .  
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

## S1 – Supplementary material

Improving Miscarriage Prevention Research – a survey exploring the Expectations of Service users and Stakeholders (IMPRESS) – Consent and survey questions

Version: V3.0

Date: 23 Nov 2023

### LIST of CONTENTS:

ITEM	Page No.
Consent	2
Survey questions	5
Survey end	16

## Participant information sheet/opening page of survey

**Study Title:** Improving Miscarriage Prevention Research – a survey exploring the Expectations of Service users and Stakeholders (IMPRESS)

**Study investigators:** Dr Joshua Odendaal, Dr Naomi Black and colleagues at the University of Warwick

Thank you for your interest in completing this short survey. This survey contains 20 questions and will take 15 minutes to complete.

This survey aims to find out what people think about the potential effectiveness of treatments for miscarriage prevention. This survey is intended for women with a history of miscarriage, their partners and healthcare professionals that are involved in treating miscarriage.

Your participation is voluntary. You can withdraw at any time whilst completing the questionnaire, and for any reason, simply by closing your browser. All responses will be anonymous, and we do not ask for any personal identifiable information. This means that once your responses have been submitted it will not be possible to withdraw your data as your individual responses cannot be identified.

This survey does not ask probing questions about previous miscarriage experiences; however, we recognise that reflecting on the subject of miscarriage may cause some participants to feel upset. Please remember that you are free to withdraw during completion of the survey. You may find it useful to find out more information about miscarriage and the support available for you at this time. Useful information sources include Tommy's, The Miscarriage Association and The Lily Mae foundation. You can find out more by clicking on the icons below.

[Insert logos of above charities with hyperlink]



Throughout the survey, we use the word 'woman' for ease of reading, but we recognise that it is possible for someone who does not identify as a woman to experience miscarriage.

This study has been granted ethical approval by NHS Health Research Authority (HRA), IRAS reference: 314809

No funding was received for completion of this project. This work will contribute to a doctoral thesis.

Data will be securely stored on the University of Warwick servers in password protected files. Access to the data will be restricted to the study investigators alone. Summaries may be presented at conferences and included in scientific publications. Data will be reviewed on completion of the research, in line with the University of Warwick data retention policy. More information about the University of Warwick Research data and privacy notice are available here: <https://warwick.ac.uk/services/idc/dataprotection/privacynotes/researchprivacynote>.

If you require any further information, please contact the study team: [impress@warwick.ac.uk](mailto:impress@warwick.ac.uk)

If you wish to make a complaint about this study, please address your complaint the Research & Impact Services at [researchgovernance@warwick.ac.uk](mailto:researchgovernance@warwick.ac.uk), if the complaint related to how we have handled your personal data please address your complaint to the Data Protection Officer at [DPO@warwick.ac.uk](mailto:DPO@warwick.ac.uk).

Further details about the study and the complaint process can be accessed here: (Link to full PIS)

## Consent

1. I confirm that I have read and understand the information for the above study. I have had the opportunity to consider the information, ask questions and have had these answered satisfactorily.
2. I understand that my participation is voluntary and that I am free to withdraw at any time whilst completing the questionnaire without giving any reason.
3. I understand that any data I enter cannot be removed from the study once submitted.
4. I understand that data collected during the study, may be looked at by individuals from the University of Warwick where it is relevant to my taking part in this study. I give permission for these individuals to have access to my data.
5. I consent for this data to be used for research purposes to investigate views on the effectiveness of miscarriage treatment in clinical research trials.
6. I confirm that it is my first time completing the survey.

I have read the above and:

I consent to take part in this study

I do not wish to participate

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**SURVEY QUESTIONS**

**SECTION ONE (DEMOGRAPHICS)**

**Question 1**

Are you a:

Woman with a history of miscarriage (Next question: 2a)

Partner of someone with a history of miscarriage (Next question: 2a)

Health care professional treating patients with a history of miscarriage (Next question: 2b)

**Question 2a**

*(If answer to Question 1: Woman with a history of miscarriage or partner of someone with a history of miscarriage)*

How many miscarriages have you or your partner suffered?

1

2

3

4

5

6 or more

Prefer not to say

**Question 2b**

*(If answer to Question 1: Health care professional who treats patients who have a history of miscarriage)*

As a health care professional treating patients with a history of miscarriage, what is your job role?

Consultant in Obstetrics & Gynaecology

Doctor working in Obstetrics & Gynaecology (Non consultant grade e.g., specialty trainee, trust grade)

Nurse specialist

Nurse

Midwife

Other (Please specify)

**SECTION TWO (INTRODUCTION TO SCENARIOS)**

We want to understand what you think would be a worthwhile treatment to prevent miscarriage.


Imagine a new treatment has been developed that prevents miscarriage. Ideally, all treatments are completely effective but this is rarely the case.

**Question 3**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Imagine 100 women with a history of miscarriage are trying to have a baby. Without treatment 50 women will have a successful pregnancy and with a new treatment 75 women will have a successful pregnancy. This is a difference of 25 successful pregnancies.

Do you think the new treatment is worthwhile?



- Yes
- No
- Unsure

**Question 4**

Now imagine that without treatment 50 women will have a successful pregnancy and with a new treatment 60 women will have a successful pregnancy. This is a difference of 10 successful pregnancies.

Do you think the new treatment is worthwhile?

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**No treatment:**  
50 successful pregnancies

**New treatment:**  
60 successful pregnancies

**Treatment difference: 10 successful pregnancies**

- Yes
- No
- Unsure

**Question 5**

Now imagine that without treatment 50 women will have a successful pregnancy and with a new treatment 55 women will have a successful pregnancy. This is a difference of 5 successful pregnancies.

Do you think the new treatment is worthwhile?

**No treatment:**  
50 successful pregnancies

**New treatment:**  
55 successful pregnancies

**Treatment difference: 5 successful pregnancies**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


- Yes
- No
- Unsure

**Question 6**

After a miscarriage, the chance of a successful next pregnancy varies. We want to understand how this affects your threshold for considering a new treatment worthwhile.

100 women with a history of miscarriage are trying to have a baby, 50 women will have a successful pregnancy without treatment. What is the smallest number of additional successful pregnancies needed to make the treatment worthwhile?

Please give a number between 0-50.



**Question 7**

What about if 70 of these women will have a successful pregnancy without treatment, what is the smallest number of additional successful pregnancies needed to make a new treatment worthwhile?

Please give a number between 0-30.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Ensignment Supérieur (ABES)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**No treatment:  
70 successful pregnancies**

**Number of additional  
successful pregnancies to be  
a worthwhile new treatment**

**Question 8**

What about if 30 of these women will have a successful pregnancy without treatment, what is the smallest number of additional successful pregnancies needed to make the new treatment worthwhile?

Please give a number between 0-70.

**No treatment:  
30 successful pregnancies**

**Number of additional  
successful pregnancies to be  
a worthwhile new treatment**

**SECTION THREE**

Additional tests may be needed before a woman undergoes a new treatment. We want to know if this affects your threshold for considering a treatment worthwhile.

**Question 9**

If the woman needs a blood test before treatment, does this change your threshold for what you would consider a worthwhile treatment?


A blood test normally lasts a couple of minutes.

- Yes
- No
- Unsure

**Question 10**

Assume that out of 100 women trying for a baby with a history of miscarriage, 50 women will have a successful pregnancy without treatment. If the women need a blood test before having the treatment, what is the smallest number of additional successful pregnancies needed to make the new treatment worthwhile?

Please give a number between 0-50.



**Question 11**

If the woman needs to first undergo a procedure to take a sample from the womb lining (biopsy) before having the treatment, does this change your threshold for considering a treatment worthwhile?

A biopsy of the womb lining normally lasts a couple of minutes and many women find it painful.

- Yes
- No
- Unsure

**Question 12**

Assume that out of 100 women trying for a baby with a history of miscarriage, 50 women will have a successful pregnancy without treatment. If the women need a **biopsy of the womb lining before having the treatment**, what is the smallest number of additional successful pregnancies needed to make the new treatment

worthwhile?

Please give a number between 0-50.



**Question 13a**

Does the number you have given change if there is a risk from the treatment?

- Yes
- No
- Unsure

**Question 13b**

*(If answer to Question 13a: Yes)*

Would the number go up or down if there was a risk from the treatment?

- It goes up
- It goes down
- Unsure

**Question 14**

Would you be willing to see fewer successful pregnancies if there was a lower chance of side effects?

- Yes
- No
- Unsure

**SECTION FOUR**

In research trials, scientists test new treatments to see if they are better than the current ones. Sometimes, these trials are stopped early because the new treatment is very clearly better than the old one, is ineffective or harmful.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignment Supérieur (ABES)


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Question 15a**

A trial to test a new treatment to prevent miscarriage needs to recruit 3,000 women to be sure that a new treatment is better than current treatment.

The initial results, after 450 women, show there are 10% more pregnancies in the new treatment group than in the current treatment group.

Do you think it is worthwhile continuing the trial?



- Yes
- No
- Unsure

**Question 15b**

(If answer to question 15a: No)

Do you think the trial should stop because:


- The new treatment is clearly better than the current one
- The new treatment is ineffective compared to the current one
- Other (Please specify)

**Question 16a**

What if there were 5% more pregnancies in the new treatment group.

Do you think it is worthwhile continuing the trial?

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



- Yes
- No
- Unsure

**Question 16b**

(If answer to question 16a: No)

Do you think the trial should stop because:

- The new treatment is clearly better than the current one
- The new treatment is ineffective compared to the current one
- Other (Please specify)


**Question 17a**

What if there were 2% more pregnancies in the new treatment group.

Do you think it is worthwhile continuing the trial?

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignment Supérieur (ABES)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



- Yes
- No
- Unsure

**Question 17b**

(If answer to question 17a: No)

Do you think the trial should stop because:

- The new treatment is clearly better than the current one
- The new treatment is ineffective compared to the current one
- Other (Please specify)


**Question 18a**

What if there was no difference in the number of pregnancies in the new treatment and current treatment group.

Do you think it is worthwhile continuing the trial?

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignment Supérieur (ABES)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Question 18b**  
(If answer to question 18a: No)

Do you think the trial should stop because:

- The new treatment is clearly better than the current one
- The new treatment is ineffective compared to the current one
- Other (Please specify)

**Question 19**

If deciding whether to continue or stop a trial based on the initial results , which is more important to you?

- Being sure that there is any difference between groups
- Seeing a large difference between groups
- Unsure

**Question 20**

Do you have any other thoughts on what affects whether a treatment to prevent miscarriage is worthwhile?

(Free text answer)

## CLOSING PAGE

Thank you for taking the time to complete this survey.

If you have any questions for the research team, please email [IMPRESS@warwick.ac.uk](mailto:IMPRESS@warwick.ac.uk)

When this study has finished, the results will be available on the Warwick University Website.

If you would like some more information about miscarriage or to learn about support available to you please click on the support charity logos below.



**MISCARRIAGE  
ASSOCIATION**  
The knowledge to help



**The  
Lily Mae  
Foundation**

er review only